Genetically engineered T cells to target EGFRvIII expressing glioblastoma
- 23 April 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 94 (3), 373-382
- https://doi.org/10.1007/s11060-009-9889-1
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaSeminars in Immunology, 2008
- EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cellsCancer Immunology, Immunotherapy, 2007
- CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor EnhancesIn vivoPersistence and Antitumor Efficacy of Adoptively Transferred T CellsCancer Research, 2006
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cellsLeukemia, 2006
- Targeted Elimination of Prostate Cancer by Genetically Directed Human T LymphocytesCancer Research, 2005
- The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune ReceptorsJournal of Immunotherapy, 2005
- Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T CellsCancer Research, 2004
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002
- Impact of chimeric immune receptor extracellular protein domains on T cell functionGene Therapy, 1999